What is HC Wainwright’s Forecast for CANF FY2026 Earnings?

Can-Fite BioPharma Ltd. (NYSE:CANF) – Investment analysts at HC Wainwright reduced their FY2026 EPS estimates for Can-Fite BioPharma in a research report issued to clients and investors on Tuesday, September 29th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($2.04) per share for the year, down from their previous forecast of ($0.68). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Can-Fite BioPharma’s current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Can-Fite BioPharma’s FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($0.64) EPS, FY2029 earnings at $0.07 EPS and FY2030 earnings at $0.38 EPS.

Can-Fite BioPharma Stock Performance

Shares of CANF stock opened at $2.21 on Thursday. The firm has a market capitalization of $2.36 million, a price-to-earnings ratio of -1.23 and a beta of 1.12. Can-Fite BioPharma has a one year low of $2.14 and a one year high of $12.73. The company has a 50 day moving average price of $2.84 and a 200 day moving average price of $3.08.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company developing orally administered small-molecule drugs for inflammatory, metabolic, liver and cancer-related diseases. The company’s research is based primarily on compounds that target the A3 adenosine receptor, a receptor believed to play a role in regulating immune and inflammatory responses.

Can-Fite’s lead candidates include piclidenoson, also known as CF101, which has been studied for conditions such as rheumatoid arthritis and psoriasis, and namodenoson, also known as CF102, which is being developed for liver-related diseases including metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma.